1. About the Database
1.1 What is Peptide Biologix?
Peptide Biologix is a free, open technical reference database for therapeutic and research peptides. It collects canonical molecular data — sequences, formulas, molecular weights, CAS numbers — and primary-literature citations in a consistent format intended for chemists, formulators, and laboratory scientists.
1.2 Who is it for?
The primary audience is technical: synthesis chemists working with difficult sequences, analytical scientists developing characterization methods, formulation scientists evaluating stability profiles, and graduate students researching peptide chemistry. Clinicians and patients will find the format too technical and not formatted as treatment guidance.
1.3 Who maintains the database, and are peptides sold here?
The database is compiled and maintained by the Peptide Biologix editorial team. No products are offered for sale on this site. The database is not affiliated with any commercial peptide supplier or institutional entity.
2. Data and Citation
2.1 Where does the data come from?
Each record cross-references at least two of: PubChem, UniProt, ChEMBL, the CAS Registry, and primary PubMed-indexed literature. The provenance for each canonical molecular value is noted inline. Where multiple sources disagree, the most recent peer-reviewed value is preferred and the disagreement is noted.
2.2 Are molecular weights monoisotopic or average mass?
Unless explicitly noted, molecular weights are reported as average molecular mass calculated from the canonical sequence using standard amino-acid residue masses. Monoisotopic masses are flagged with the note “monoisotopic” in the relevant cell of the molecular specifications table.
2.3 Can I cite a record?
Yes. For academic work, cite the underlying primary literature linked inline; cite the Peptide Biologix record only when the database itself is the unit of compilation or comparison.
2.4 What licensing applies?
Data points (molecular weights, sequences, CAS numbers, formulas) are facts and not copyrightable. The editorial text in monographs is published under a Creative-Commons-equivalent free-reuse policy provided you credit the database and link to the source record. Tables may be reproduced freely.
3. Editorial Process
3.1 How often is the database updated?
All records are reviewed quarterly. Major revisions are triggered by new clinical-trial data, novel structural elucidations, or regulatory actions affecting a compound. Minor corrections are integrated continuously.
3.2 How do I request a new monograph?
Send a request via the contact page with the compound name, canonical sequence (if known), at least one PubMed citation establishing research relevance, and a brief justification. Requests are triaged monthly.
3.3 How do I report an error?
Send the monograph URL, the specific data point, the proposed correction, and a verifiable source. Use the structured format shown on the contact page to accelerate processing.
4. Regulatory and Use
4.1 Are these peptides approved drugs?
Some are (tesamorelin, PT-141, oxytocin, vasopressin, triptorelin, gonadorelin). Many are investigational compounds with no approved human or veterinary use. Each monograph notes regulatory status where applicable.
4.2 Can I use these data for medical decisions?
No. The database is for laboratory research, chemistry education, and analytical method development. It is not a clinical reference and does not constitute medical advice. Consult qualified healthcare professionals for any clinical decision.
4.3 What about the regulatory status in my country?
Regulatory status varies considerably by jurisdiction and changes frequently. Each monograph notes U.S. FDA approval or bulk compounding status (current as of April 22, 2026) where applicable. Consult your applicable regulatory authority and institutional compliance office before procuring, possessing, or working with any peptide.